LNH-98.5
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
N = 399
- Population
- Previously untreated diffuse large-B-cell lymphoma, aged 60 to 80 years.
- Design
- Randomised comparison by the Groupe d'Etudes des Lymphomes de l'Adulte (GELA) of eight cycles of CHOP every three weeks with or without rituximab on day 1 of each cycle. The trial name LNH-98.5 and the GELA attribution come from the title of the 10-year report; the phase is not stated in the 2002 abstract or the 10-year report, and no registry number appears in the abstract.
- Primary endpoint
- EFS
- Arms
- CHOP (control, n = 197): Eight cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) every three weeks
- CHOP plus rituximab (experimental, n = 202): Eight cycles of CHOP every three weeks with rituximab on day 1 of each cycle
- People
- Coiffier B, senior author Gisselbrecht C, Groupe d'Etudes des Lymphomes de l'Adulte (GELA)
Δ CR rate+13 pointsΔ 120-month PFS+16.5 pointsΔ 120-month OS+15.9 points
Show the numbers
| Endpoint | Analysis | CHOP plus rituximab | CHOP | Effect |
|---|---|---|---|---|
| CR rateRandomised patients (197 CHOP, 202 CHOP plus rituximab); the abstract does not label the analysis population | primaryCoiffier 2002 | 76% | 63% | P=0.005 |
| PFS399 patients aged 60 to 80 years with DLBCL randomised in LNH-98.5; the abstract does not label the analysis population | long term-updatemedian follow-up 10 yearsCoiffier 2010 | 36.5% at 10 y | 20% at 10 y | Ten-year progression-free survival as stated in the abstract; no p-value or confidence interval is given there. |
| OS399 patients aged 60 to 80 years with DLBCL randomised in LNH-98.5; the abstract does not label the analysis population | long term-updatemedian follow-up 10 yearsCoiffier 2010 | 43.5% at 10 y | 27.6% at 10 y | Ten-year overall survival as stated in the abstract; no p-value or confidence interval is given there. |
| Endpoint | Analysis | CHOP plus rituximab | CHOP | Effect |
|---|---|---|---|---|
| CR rateRandomised patients (197 CHOP, 202 CHOP plus rituximab); the abstract does not label the analysis population | primaryCoiffier 2002 | 76% | 63% | P=0.005 |
| PFS399 patients aged 60 to 80 years with DLBCL randomised in LNH-98.5; the abstract does not label the analysis population | long term-updatemedian follow-up 10 yearsCoiffier 2010 | 36.5% at 10 y | 20% at 10 y | Ten-year progression-free survival as stated in the abstract; no p-value or confidence interval is given there. |
| OS399 patients aged 60 to 80 years with DLBCL randomised in LNH-98.5; the abstract does not label the analysis population | long term-updatemedian follow-up 10 yearsCoiffier 2010 | 43.5% at 10 y | 27.6% at 10 y | Ten-year overall survival as stated in the abstract; no p-value or confidence interval is given there. |
Appears in
Sources
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42.
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-5.